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Acetaminophen, also known as APAP or paracetamol, is one of the most widely used
analgesics (pain reliever) and antipyretics (fever reducer). According to the U.S. Food and
Drug Administration, currently there are 235 approved prescription and over-the-counter
drug products containing acetaminophen as an active ingredient. When used as directed,
acetaminophen is very safe and effective; however when taken in excess or ingested with
alcohol hepatotoxicity and irreversible liver damage can arise. In addition to well known use
pain relief and fever reduction, recent laboratory and pre-clinical studies have demonstrated
that acetaminophenmay also have beneﬁcial effects on blood glucose levels, skeletal mus-
cle function, and potential use as cardioprotective and neuroprotective agents. Extensive
laboratory and pre-clinical studies have revealed that these off-label applications may be
derived from the ability of acetaminophen to function as an antioxidant. Herein, we will
highlight these novel applications of acetaminophen, and attempt, where possible, to high-
light how these ﬁndingsmay lead to new directions of inquiry and clinical relevance of other
disorders.
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INTRODUCTION
Acetaminophen (N-Acetyl-4-aminophenol) also knownas“APAP”
or “paracetamol” is one of the most widely used medicines in
the United States. According to the data from IMS Health, ∼24.6
billion doses of acetaminophen were sold in 2008. The market
demand for acetaminophen is growing. Recent data has demon-
strated a 28% growth in the market sales of acetaminophen
between 2004 and 2008with sales approaching approximately $2.6
billion in 2008 alone (Data from IMS Health).
Acetaminophen exhibits both analgesic and antipyretic prop-
erties and has been widely used as an active ingredient in many
approved drugs. According to the U.S. Food and Drug Adminis-
tration (FDA), 479 drugs contain acetaminophen (Table 1). As of
August 2011, 235 out of the 479 acetaminophen-containing drugs
exhibit active approval status, which include 214 prescription
drug products owned by 31 companies and 21 over-the-counter
(OTC) drug products produced by nine companies (Tables 1
and 2). Given its wide use and easy availability, scientists have
recently begun to examine acetaminophen for off-label appli-
cations. Herein, we will investigate these potential applications,
and attempt, where possible, to highlight how these ﬁndings may
lead to new directions of inquiry and clinical relevance of other
disorders.
CHRONIC ACETAMINOPHEN INGESTION CAN IMPROVE
BLOOD GLUCOSE CONTROL
Although a toxic dose of acetaminophen (3 h following 500mg
APAP/kg body weight) can rapidly induce hyperglycemia (Hin-
son et al., 1984) and acute liver failure secondary to clinical
acetaminophen overdose can further impair the peripheral uptake
of glucose (Clark et al., 2001), recent animal studies have demon-
strated that acetaminophen, when taken at lower dosages (20–
30mg/kg body weight) exhibits an ability to lower blood glucose
levels in several animal diseasemodels, including diabetes, high-fat
(HF) diet induced obesity, and aging.
Using a streptozotocin (STZ)-induced diabetic mice model,
Shertzer et al. (2008) showed that acetaminophen at 20mg/kg
body weight is able to normalize STZ-induced increases in blood
glucose levels. This effect appears to be associated with protection
against STZ-induced destruction of pancreatic beta-cells given the
ﬁnding that acetaminophen injection appears to be associatedwith
the maintenance of pancreatic insulin synthesis (Shertzer et al.,
2008). Like that observed in the STZ model, acetaminophen at 20
or 30mg/kg body weight has also been reported to prevent hyper-
glycemia in animals fed a HF diet (Shertzer et al., 2008, 2010).
In addition to preventing hyperglycemia, acetaminophen inges-
tion is also associated with the restoration of fasting insulin levels,
improvements in glucose tolerance, and an increased ability of the
HF-fed mice to boost blood insulin levels after a glucose challenge
(Shertzer et al., 2008, 2010). Although the exact mechanism(s)
remains unclear, these effects, like that seen in the rat STZ model,
have been postulated to arise from improvements in pancreatic
insulin synthesis/secretion.
Research using both humans and animal models have demon-
strated that the incidence of insulin resistance increases with
age (Houmard et al., 1995; Wu et al., 2009a). Wu et al. (2009a)
using Fisher 344×Brown Norway (F344BN) aging rat model
have shown that age-associated increases in blood glucose can
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Table 1 | Approved drug products containing acetaminophen as an
active ingredient.
Approved drugs Companies
Prescription drug products (Rx) 214 31
Over-the-counter drug products (OTC) 21 9
Discontinued drug products 244 60
Total 479 100
Table 2 | Over-the-counter drug products (OTC) containing
acetaminophen.
Company name Drug name
Actavis mid Atlantic Infants’ Feverall; acetaminophen.
G andW labs Acephen
McNeil consumer healthcare Tylenol
Novartis Excedrin (migraine); tavist
allergy/sinus/headache
Ohm labs Acetaminophen
Perrigo Acetaminophen; acetaminophen,
aspirin and caffeine
Polymedica Neopap
Ranbaxy Acetaminophen
Schering plow Drixoral plus
Data source: the orange book from FDA.
be corrected by chronic acetaminophen treatment at the dosage
of 30mg/kg body weight. It has been postulated that this
effect was predicated, at least in part, on the ability of aceta-
minophen to diminish age-related losses in amount of mus-
cle glucose transporter-4 (Glut4) expression (Wu et al., 2009a).
Further study demonstrated that acetaminophen treatment was
also associated with an attenuation of muscle reactive oxygen
species (ROS) levels and in the amount of proteins that become
oxidatively modiﬁed (Wu et al., 2009a). It has been shown
that prolonged mitogen activated protein kinase (MAPK) acti-
vation is associated with decreased Glut4 expression (Fujishiro
et al., 2001; Carlson et al., 2003) and Glut4 translocation in
response to insulin (Bandyopadhyay et al., 2001; Izawa et al., 2005;
D’Alessandris et al., 2007). Interestingly, works done by Wu et al.
(2009a) showed that acetaminophen treatment could normalize
the marked increases in p38- and ERK–MAPK activation seen in
aged muscle. Taken together, these ﬁndings suggests that aceta-
minophen might function to improve blood glucose levels by
employing multiple mechanisms including decreases in intracel-
lular ROS levels, diminished aging-associated MAPK hyperphos-
phorylation and by increasing muscle Glut4 expression (Wu et al.,
2009a).
LONG TERM ACETAMINOPHEN INGESTION CAN IMPROVE SKELETAL
MUSCLE STRUCTURE AND FUNCTION
In addition to the beneﬁcial effect of acetaminophen on reliev-
ing muscle soreness and pain (Prior et al., 2011), recent studies
have suggested that acetaminophen can improve aged skeletal
muscle structure and function (sarcopenia). Wu et al. (2009b)
ﬁrstly reported that chronic acetaminophen treatment at 30mg/kg
body weight is able to decrease the amount of aging-associated
myocyte apoptosis and increase myocyte size (muscle ﬁber cross
sectional area), with this latter effect occurring most likely asso-
ciated with an increase in myosin and actin expression in aged
muscle. These effects are believed to be mediated, at least in part,
via reductions in the amount of oxidative and nitrosative stress
as acetaminophen intervention lowers the amount of superoxide
and the abundance of oxidatively modiﬁed proteins (Wu et al.,
2009a). It also appears that acetaminophen treatment reduces
the phosphorylation of eukaryotic initiation factor 2a (eIF2a;
Wu et al., 2010), a key protein translational factor which when
phosphorylated in response to stress leads to the inhibition of
protein translational initiation (Kimball, 1999). Other data has
demonstrated that acetaminophen can decrease muscle reactive
nitrogen species (RNS) as evidenced by reduced expression of
inducible NOS (iNOS) and S-nitrosylation of Akt (Wu et al.,
2009b). The Akt/protein kinase B is critical regulator of cellular
homeostasis and functions to control cellular anabolism (pro-
tein synthesis, glucose uptake, and metabolism) and cell fate
(proliferation, apoptosis; Wu et al., 2011). Akt S-nitrosylation
impairs Akt kinase activity (Carvalho-Filho et al., 2005; Yasukawa
et al., 2005; Wu et al., 2009b), which if not corrected can lead
to a dysregulation of Akt signaling. Importantly, the restoration
of Akt function by acetaminophen is associated with improve-
ments in protein translational signaling [increased phosphoryla-
tion/activation of S6 ribosomal protein (Ser235/236) and transla-
tion initiation factor eIF4E (Ser209)], increases in the amount of
muscle Glut4,myosin, and actin, along with a decrease in myocyte
apoptosis and the prevention of age-associated hyperglycemia
(Wu et al., 2009a,b, 2010).
The positive effects of acetaminophen on skeletal muscle struc-
ture and function have also been proved in other experimental
sitting. Shertzer et al. (2008) reported that acetaminophen is able
to prevent HF diet induced decreases in lean muscle volume and
body water retention. Trappe et al. (2011) demonstrated during
12weeks of knee extensor progressive resistance exercise training
that acetaminophen (4 g/day) can increase exercise-induced mus-
cle (quadriceps) hypertrophy and strength in older adults when
compared to that seen with placebo, although muscle (vastus lat-
eralis) protein content, muscle water content, and myosin heavy
chain distribution did not increase. Interestingly, increased mus-
cle volume and strength by acetaminophen appears not to be
mediated by cyclooxygenase (COX), as the expression of COX-
1 and COX-2 was not changed with acetaminophen consumption
(Trappe et al., 2011). Importantly, acetaminophen at 4 g/day for
12weeks when used in combination with resistance training did
not alter blood creatinine and ALT levels (Trappe et al., 2011), a
ﬁnding which suggests that this dosage does not cause liver or
kidney damage. Interestingly, the effect of acetaminophen and
exercise combination appears dependent on type of exercise as
acetaminophen has been reported to suppress the protein synthe-
sis response in skeletal muscle after eccentric resistance exercise
(Trappe et al., 2002), which appears to be mediated through
decreasing exercise-induced PGF(2alpha) expression and hence
affecting the anabolic response of muscle to eccentric resistance
exercise (Trappe et al., 2001). Whether a similar ﬁnding exists
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for other types of exercise modalities (e.g., aerobic) is currently
unclear.
ACETAMINOPHEN POSSESSES CARDIOPROTECTIVE AND
NEUROPROTECTIVE PROPERTIES
Clinical studies have suggested that the risk for major cardiovas-
cular events will be increased if acetaminophen is taken frequently
(≥22 days/month) or at high doses (15 tablets/week; Chan et al.,
2006). Nonetheless, when used properly, acetaminophen has been
shown to exhibit cardioprotective effects. Using an isolated guinea
pig heart model, several studies have shown that acetaminophen
(0.35mM) can increase coronary vascular resistance and posi-
tive inotropy (Merrill et al., 2001), attenuate ischemia-reduced
monophasic action potentials (Merrill and Goldberg, 2001), and
improve left ventricular contractility (rate of developed pressure)
during post ischemia–reperfusion (Merrill et al., 2001; Merrill,
2002). Further examination using electron microscopy has sug-
gested that acetaminophen can preserve left ventricular myoﬁbril-
lar ultrastructure in the reperfusedmyocardium, including protec-
tion against ischemia/reperfusion-induced diffused and blurred
Z lines, the presence of contraction bands, and swollen, sparsely
packed mitochondria (Merrill et al., 2001). Using two dog mod-
els of ventricular arrhythmias induced by regional myocardial
ischemia/reperfusion or ouabain (25μg/kg), Merrill et al. (2007)
demonstratedan anti-arrhythmic effect for acetaminophen, and
found that acetaminophen (15mg/kg, i.v.) signiﬁcantly reduce the
number of ventricular ectopic beats during ischemia and reperfu-
sion, the amount of ouabain-induced ventricular premature beats,
ventricular salvo, ventricular bigeminy, and non-sustained ven-
tricular arrhythmia. In the iron-overloaded gerbil, Walker et al.
(2007) have demonstrated that acetaminophen is able to prevent
iron overload-induced cardiac structural and functional changes,
including alterations in cardiac rhythm, ventricular distension,
reductions in left ventricular ejection fraction, decreases in frac-
tional shortening, and decreases in mortality (Walker et al., 2009).
Mauger et al. (2010) reported that ingestion of acetaminophen
(1.5 g) can improve the performance of a 10-mile cycle time trial
(TT) with no difference in exertion or perceived pain, and that
cyclists who ingested acetaminophen had a higher mean power
output and heart rate. Merrill et al. (2004) using a myocardial
infarction dog model showed that acetaminophen at 30mg/kg
body weight is able to decrease infarct size. These researchers
also showed acetaminophen treatment can reduce cardiac dam-
age, including swollen mitochondria and fragmented nucleus
(Merrill et al., 2004). Conversely, others using different animal
models did not show beneﬁcial effects on infarct size in non-
preconditioned rats (Dai and Kloner, 2003) or in coronary artery
occlusion/reperfusion rabbits (Hale andKloner,2004),however all
suggest that acetaminophen is a safe drug in the postmyocardial
infarction setting (Dai and Kloner, 2003; Hale and Kloner, 2004;
Leshnower et al., 2006). Further studies deﬁning detailed condi-
tions are needed to verify the protective effect of acetaminophen
on infarct size.
It has also been reported that acetaminophen has neuro-
protective effects. Maharaj et al. (2004) reported that aceta-
minophen (0.25–1mM) treatment ex vivo can inhibit cyanide-
induced superoxide anion generation and lipid peroxidation
in rat brain homogenates. Further animal study has suggested
the acetaminophen (100mg/kg/day, i.p.) can inhibit quinolinic
acid (QA)-induced lipid peroxidation, superoxide anion gener-
ation, and cell damage in the rat hippocampus (Maharaj et al.,
2006). Naziroglu et al. (2009) also reported acetaminophen
(5–100mg/kg) can reduce brain and microsomal lipid peroxida-
tion, while it also increases brain vitamin E levels and microso-
mal glutathione peroxidase (GSH-Px) activity. In addition, Bis-
aglia et al. (2002) used rat primary hippocampal neurons and
rat pheochromocytoma cells demonstrated that acetaminophen
(100μM) can protect against amyloid beta-fragment-induced
impairment ofmitochondrial redox activity, increases in phospho-
lipid peroxidation, and apoptotic nuclear fragmentation, suggest-
ing a possible therapeutic effect of acetaminophen on Alzheimer’s
disease.
ACETAMINOPHEN EXHIBITS POTENT ANTIOXIDANT
ACTIVITY
It is well known that acetaminophen overdose can lead to oxida-
tive stress and induce hepatic and renal damage (Ghosh et al.,
2010; Agarwal et al., 2011). Acetaminophen is initially metabo-
lized in the liver, and generates the toxic metabolite, N -acetyl-p-
benzoquinone imine (NAPQI). NAPQI can be efﬁciently detoxi-
ﬁed by glutathione (GSH) which is an important cellular antiox-
idant for detoxiﬁcation of drugs and foreign chemicals. When
overdosed with acetaminophen, intracellular glutathione can be
depleted within 1–4 h (Al-Turk and Stohs, 1981; Porubek et al.,
1987; Lores Arnaiz et al., 1995), resulting in accumulation of
intracellular reactive oxygen and nitrogen species (ROS/RNS), and
oxidative/nitrosative stress will occur. The over-produced NAPQI
can covalently bind to the cysteinyl thiol groups of cellular proteins
and form protein-(cystein-S-yl)-APAP adducts (Hoffmann et al.,
1985), whichmay impair protein function. Given this mechanism,
antioxidant therapy using N -acetylcysteine (NAC) is commonly
used to attenuate acetaminophen-induced hepatotoxicity.
Interestingly, extensive animal and in vitro studies have sug-
gested that acetaminophen possesses remarkable antioxidant
properties when used within the therapeutic dosage. Aceta-
minophen is phenolic in structure with a substituent at the para
position relative to the hydroxyl group (Figure 1) which allows
it to react with reactive species (Dinis et al., 1994; Shertzer et al.,
2008). For example, Shertzer et al. (2008) using cell-free assay
systems demonstrated that acetaminophen at a concentrations
of 2–10μM is able to directly scavenge reactive oxygen. Nam
et al. (2009) found that acetaminophen has higher reactivity
FIGURE 1 | Structure of acetaminophen (N-Acetyl-4-aminophenol).The
phenolic structure with a substituent at the para position relative to the
hydroxyl group allows acetaminophen to react with reactive species and
possesses antioxidant activity.
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with peroxyl radicals than many widely used phenolic antiox-
idants, including ubiquitous butylated hydroxytoluene (BHT).
Other in vitro studies showed that acetaminophen can signiﬁcantly
inhibit hemoprotein-induced lipid peroxidation by its ability to
reducing ferryl heme to its ferric state and the quenching glo-
bin radicals (Boutaud et al., 2010). Acetaminophen has also be
shown to reduce the degree of low-density lipoproteins (LDL)
hydroperoxides induced by Cu2+ ions (Ozsoy and Pabuccuoglu,
2007) or myeloperoxidase in presence of nitrite and hydrogen
peroxide (Chou and Greenspan, 2002). Several studies have also
demonstrated that acetaminophen can directly scavenge perox-
ynitrite (Van Dyke et al., 1998; Rork et al., 2006; Schildknecht
et al., 2008), a highly reactive oxidant and nitrating agent that
can oxidize lipids, proteins, and nucleic acids. Nam et al. (2009)
showed that when nitrogen is incorporated into the phenolic
ring the antioxidant activity of acetaminophen is greatly reduced
and that this ﬁnding seems to be associated with increased O–
H bond dissociation enthalpy. However, this structural change
increases the efﬁcacy of acetaminophen to act as an inhibitor
of lipid hydroperoxide biosynthesis by soybean lipoxygenases-
1 (sLOX-1) (Nam et al., 2009) and further evidences suggested
that altered acidity of the phenolic O–H may lead to chelation of
the catalytic non-heme iron atom in sLOX-1 (Nam et al., 2009).
Taken together, it appears that the structure of the acetaminophen
phenolic ring is critical for its pharmacological and antioxidant
properties.
Ex vivo and in vivo animal studies have suggested that aceta-
minophen can effectively reduce ROS/RNS in multiple tissue
types. Back in 1983, DuBois et al. (1983) reported that aceta-
minophen had antioxidant effects in the rat liver. Shertzer
et al. (2008) also showed that acetaminophen (20mg/kg) can
decrease liver mitochondrial H2O2 formation in both con-
trol and HF diet fed mice. Wu et al. (2009a,b, 2010) demon-
strated that acetaminophen treatment at 30mg/kg for 6months
can attenuate aging-increased skeletal muscle ROS content, the
amount of proteins that are oxidatively modiﬁed, and protein
S-nitrosylation, suggesting acetaminophen can decrease oxida-
tive/nitrosative stress during aging. Using a rhabdomyolysis-
induced renal failure animal model, Boutaud et al. (2010) showed
that acetaminophen (100mg/kg, i.p.) can signiﬁcantly decrease
myoglobin-derived radical species and that this ﬁnding was asso-
ciated with reduced renal damage and improved renal function.
Usinga HF fed animal model, Shertzer et al. (2010) demonstrated
that acetaminophen (30mg/kg/day) was able to inhibit produc-
tion of reactive oxygen species (at least partially via inhibition
of NADPH oxidase activity) and lipid peroxidation in white adi-
pose tissue (WAT) which improved glucose tolerance and insulin
sensitivity in HF animals.
Although not yet well understood, the cardioprotective effects
of acetaminophen seem to relate to its antioxidant property
(Merrill and Goldberg, 2001; Merrill et al., 2001; Merrill, 2002;
Rork et al., 2006; Hadzimichalis et al., 2007; Walker et al.,
2007, 2009; Kakarla et al., 2010). Using Langendorff-perfused
guinea pig hearts, Hadzimichalis et al. (2007) reported that aceta-
minophen (0.35mM) can reduce mitochondrial swelling, and
inhibit the mitochondrial permeability transition pore-induced
FIGURE 2 | Summary of acetaminophen therapeutic effects. In addition
to the clinically proven analgesic/antipyretic properties, laboratory and
pre-clinical studies demonstrated that acetaminophen has other beneﬁcial
effects that would increase clinical application of acetaminophen. However,
clinical studies are needed to ensure its safety, efﬁciency, and proper
dosage.
apoptotic pathway and mitochondrial cytochrome C release
in heart with induced low-ﬂow global myocardial ischemia.
Merrill et al. (2001) demonstrated that acetaminophen can sig-
niﬁcantly attenuate the burst of hydroxyl radicals during the
ﬁrst 10min of reperfusion, and block 3-morpholinosydnominine
(SIN-1)-induced peroxynitrite generation. Kakarla et al. (2010)
have found that chronic acetaminophen treatment at 30mg/kg
body weight is able to attenuate aging-associated increases in
cardiac oxidative (superoxide) and nitrosative (protein nitrotyro-
sylation) stresses, caspase-3 activation, and apoptosis in F344BN
rats. Rork et al. (2006) reported that acetaminophen (0.35mM)
can reduce peroxynitrite in the isolated guinea pig myocardium
and that this ﬁnding was associated with an attenuated activation
of MMP-2 and decreased cleavage of troponin I (TnI) following
ischemia/reperfusion. Therefore, cardioprotective effects of aceta-
minophen are at least partiallymediated by reducing tissue reactive
oxygen and nitrogen species.
CONCLUSION AND PERSPECTIVES
Recent experimental data suggests that acetaminophen may
have several remarkable effects other than its well known anal-
gesic/antipyretic properties. Thus far, acetaminophen has been
shown to improve blood glucose control, improve skeletal muscle
structure and function in the aged, and that this agent exhibits
cardioprotective and neuroprotective effects (Figure 2). Current
laboratory andpre-clinical studies have revealed thatmanyof these
ﬁndings can be linked to its incredible antioxidant properties. It is
also worth noting that since acetaminophen overdose or ingestion
with alcohol can cause hepatotoxicity and death, well controlled
clinical studies must be conducted to ensure the safety and efﬁ-
ciency of acetaminophenbefore its clinical application for off-label
application.
ACKNOWLEDGMENTS
The authors would like to acknowledge the support of the Hunt-
ington VA Medical Center for laboratory space and equipment.
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery November 2011 | Volume 2 | Article 72 | 4
Blough andWu Novel application of acetaminophen
REFERENCES
Agarwal, R., Macmillan-Crow, L. A.,
Rafferty, T. M., Saba, H., Roberts, D.
W., Fifer, E. K., James, L. P., and Hin-
son, J. A. (2011). Acetaminophen-
induced hepatotoxicity in mice
occurs with inhibition of activity
and nitration of mitochondrial
manganese superoxide dismutase.
J. Pharmacol. Exp. Ther. 337,
110–116.
Al-Turk, W. A., and Stohs, S. J. (1981).
Hepatic glutathione content and aryl
hydrocarbon hydroxylase activity of
acetaminophen-treated mice as a
function of age. Drug Chem. Toxicol.
4, 37–48.
Bandyopadhyay,G., Sajan,M. P.,Kanoh,
Y., Standaert, M. L., Quon, M. J.,
Reed, B. C., Dikic, I., and Farese, R.
V. (2001). Glucose activates protein
kinase C-zeta/lambda through
proline-rich tyrosine kinase-2,
extracellular signal-regulated
kinase, and phospholipase D: a
novel mechanism for activating
glucose transporter translocation. J.
Biol. Chem. 276, 35537–35545.
Bisaglia, M., Venezia, V., Piccioli, P.,
Stanzione, S., Porcile, C., Russo, C.,
Mancini, F., Milanese, C., and Schet-
tini, G. (2002). Acetaminophen
protects hippocampal neurons
and PC12 cultures from amyloid
beta-peptides induced oxidative
stress and reduces NF-kappaB
activation. Neurochem. Int. 41,
43–54.
Boutaud, O., Moore, K. P., Reeder,
B. J., Harry, D., Howie, A. J.,
Wang, S., Carney, C. K., Master-
son, T. S., Amin, T., Wright, D.
W., Wilson, M. T., Oates, J. A.,
and Roberts, L. J. II. (2010). Aceta-
minophen inhibits hemoprotein-
catalyzed lipid peroxidation and
attenuates rhabdomyolysis-induced
renal failure. Proc. Natl. Acad. Sci.
U.S.A. 107, 2699–2704.
Carlson, C. J., Koterski, S., Sciotti, R.
J., Poccard, G. B., and Rondinone,
C. M. (2003). Enhanced basal acti-
vation of mitogen-activated protein
kinases in adipocytes from type 2
diabetes: potential role of p38 in the
downregulation of GLUT4 expres-
sion. Diabetes 52, 634–641.
Carvalho-Filho, M. A., Ueno, M.,
Hirabara, S. M., Seabra, A. B., Car-
valheira, J. B., De Oliveira, M. G.,
Velloso, L. A., Curi, R., and Saad, M.
J. (2005). S-nitrosation of the insulin
receptor, insulin receptor substrate
1, and protein kinase B/Akt: a novel
mechanism of insulin resistance.
Diabetes 54, 959–967.
Chan, A. T., Manson, J. E., Albert, C.
M., Chae, C. U., Rexrode, K. M.,
Curhan, G. C., Rimm, E. B., Willett,
W. C., and Fuchs, C. S. (2006). Non-
steroidal antiinﬂammatory drugs,
acetaminophen, and the risk of car-
diovascular events. Circulation 113,
1578–1587.
Chou, T. M., and Greenspan, P.
(2002). Effect of acetaminophen
on the myeloperoxidase-hydrogen
peroxide-nitrite mediated oxidation
of LDL. Biochim. Biophys. Acta 1581,
57–63.
Clark, S. J., Shojaee-Moradie, F., Croos,
P., Seed, P. T., Umpleby, A. M.,Wen-
don, J. A., and Miell, J. (2001). Tem-
poral changes in insulin sensitiv-
ity following the development of
acute liver failure secondary to aceta-
minophen. Hepatology 34, 109–115.
Dai,W., andKloner,R.A. (2003). Effects
of acetaminophen on myocardial
infarct size in rats. J. Cardiovasc.
Pharmacol. Ther. 8, 277–284.
D’Alessandris, C., Lauro, R., Presta,
I., and Sesti, G. (2007). C-reactive
protein induces phosphorylation
of insulin receptor substrate-1 on
Ser307 and Ser 612 in L6 myocytes,
thereby impairing the insulin sig-
nalling pathway that promotes
glucose transport. Diabetologia 50,
840–849.
Dinis, T. C., Maderia, V. M.,
and Almeida, L. M. (1994).
Action of phenolic derivatives
(acetaminophen, salicylate, and
5-aminosalicylate) as inhibitors of
membrane lipid peroxidation and
as peroxyl radical scavengers. Arch.
Biochem. Biophys. 315, 161–169.
DuBois, R. N., Hill, K. E., and Burk,
R. F. (1983). Antioxidant effect of
acetaminophen in rat liver. Biochem.
Pharmacol. 32, 2621–2622.
Fujishiro, M., Gotoh, Y., Katagiri, H.,
Sakoda, H., Ogihara, T., Anai, M.,
Onishi, Y., Ono, H., Funaki, M.,
Inukai, K., Fukushima, Y., Kikuchi,
M., Oka, Y., and Asano, T. (2001).
MKK6/3 and p38 MAPK path-
way activation is not necessary
for insulin-induced glucose uptake
but regulates glucose transporter
expression. J. Biol. Chem. 276,
19800–19806.
Ghosh, J., Das, J., Manna, P., and Sil, P.
C. (2010). Acetaminophen induced
renal injury via oxidative stress and
TNF-alpha production: therapeutic
potential of arjunolic acid. Toxicol-
ogy 268, 8–18.
Hadzimichalis, N. M., Baliga, S. S.,
Golfetti, R., Jaques, K. M., Firestein,
B. L., and Merrill, G. F. (2007).
Acetaminophen-mediated car-
dioprotection via inhibition of
the mitochondrial permeability
transition pore-induced apoptotic
pathway. Am. J. Physiol. Heart Circ.
Physiol. 293, H3348–H3355.
Hale, S. L., and Kloner, R. A. (2004).
Acetaminophen and experimental
acute myocardial infarction. Cardio-
vasc. Drugs Ther. 18, 121–125.
Hinson, J. A., Han-Hsu, H., Mays, J. B.,
Holt, S. J., Mclean, P., and Ketterer,
B. (1984). Acetaminophen-induced
alterations in blood glucose and
blood insulin levels in mice. Res.
Commun. Chem. Pathol. Pharmacol.
43, 381–391.
Hoffmann, K. J., Streeter, A. J., Axwor-
thy, D. B., and Baillie, T. A. (1985).
Identiﬁcation of the major covalent
adduct formed in vitro and in vivo
between acetaminophen and mouse
liver proteins. Mol. Pharmacol. 27,
566–573.
Houmard, J. A., Weidner, M. D., Dolan,
P. L., Leggett-Frazier, N., Gavigan,
K. E., Hickey, M. S., Tyndall, G. L.,
Zheng, D., Alshami, A., and Dohm,
G. L. (1995). Skeletal muscle GLUT4
protein concentration and aging in
humans. Diabetes 44, 555–560.
Izawa, Y., Yoshizumi, M., Fujita, Y.,
Ali, N., Kanematsu, Y., Ishizawa, K.,
Tsuchiya, K., Obata, T., Ebina, Y.,
Tomita, S., and Tamaki, T. (2005).
ERK1/2 activation by angiotensin
II inhibits insulin-induced glucose
uptake in vascular smooth muscle
cells. Exp. Cell Res. 308, 291–299.
Kakarla, S. K., Fannin, J. C., Keshavarz-
ian, S., Katta,A., Paturi, S.,Nalabotu,
S. K., Wu, M., Rice, K. M., Manzoor,
K., Walker, E. M. Jr., and Blough, E.
R. (2010). Chronic acetaminophen
attenuates age-associated increases
in cardiac ROS and apoptosis in the
Fischer BrownNorway rat.Basic Res.
Cardiol. 105, 535–544.
Kimball, S. R. (1999). Eukaryotic initia-
tion factor eIF2. Int. J. Biochem. Cell
Biol. 31, 25–29.
Leshnower, B. G., Sakamoto, H., Zee-
shan, A., Parish, L. M., Hinmon, R.,
Plappert, T., Jackson, B. M., Gor-
man, J. H. III., and Gorman, R.
C. (2006). Role of acetaminophen
in acute myocardial infarction. Am.
J. Physiol. Heart Circ. Physiol. 290,
H2424–H2431.
Lores Arnaiz, S., Llesuy, S., Cutrin, J.
C., and Boveris, A. (1995). Oxida-
tive stress by acute acetaminophen
administration in mouse liver. Free
Radic. Biol. Med. 19, 303–310.
Maharaj, D. S., Saravanan, K. S.,
Maharaj, H., Mohanakumar, K. P.,
andDaya, S. (2004). Acetaminophen
and aspirin inhibit superoxide anion
generation and lipid peroxidation,
and protect against 1-methyl-
4-phenyl pyridinium-induced
dopaminergic neurotoxicity in rats.
Neurochem. Int. 44, 355–360.
Maharaj, H., Maharaj, D. S., and Daya,
S. (2006). Acetylsalicylic acid and
acetaminophen protect against
oxidative neurotoxicity. Metab.
Brain Dis. 21, 189–199.
Mauger, A. R., Jones, A. M., and
Williams, C. A. (2010). Inﬂuence
of acetaminophen on performance
during time trial cycling. J. Appl.
Physiol. 108, 98–104.
Merrill, G., Mcconnell, P., Vandyke,
K., and Powell, S. (2001). Coro-
nary and myocardial effects of
acetaminophen: protection during
ischemia-reperfusion. Am. J. Phys-
iol. Heart Circ. Physiol. 280, H2631–
H2638.
Merrill, G. F. (2002). Acetaminophen
and low-ﬂow myocardial ischemia:
efﬁcacy and antioxidant mecha-
nisms. Am. J. Physiol. Heart Circ.
Physiol. 282, H1341–H1349.
Merrill, G. F., and Goldberg, E.
(2001). Antioxidant properties
of acetaminophen and cardio-
protection. Basic Res. Cardiol. 96,
423–430.
Merrill, G. F., Merrill, J. H., Golfetti, R.,
Jaques, K. M., Hadzimichalis, N. S.,
Baliga, S. S., and Rork, T. H. (2007).
Antiarrhythmic properties of aceta-
minophen in the dog.Exp. Biol.Med.
(Maywood) 232, 1245–1252.
Merrill, G. F., Rork, T. H., Spiler, N.
M., and Golfetti, R. (2004). Aceta-
minophen and myocardial infarc-
tion in dogs. Am. J. Physiol. Heart
Circ. Physiol. 287, H1913–H1920.
Nam, T. G., Nara, S. J., Zagol-Ikapitte,
I., Cooper, T., Valgimigli, L., Oates,
J. A., Porter, N. A., Boutaud, O.,
and Pratt, D. A. (2009). Pyridine
and pyrimidine analogs of aceta-
minophen as inhibitors of lipid per-
oxidation and cyclooxygenase and
lipoxygenase catalysis. Org. Biomol.
Chem. 7, 5103–5112.
Naziroglu, M., Uguz, A. C., Kocak, A.,
and Bal, R. (2009). Acetaminophen
at different doses protects brain
microsomal Ca2+-ATPase and the
antioxidant redox system in rats. J.
Membr. Biol. 231, 57–64.
Ozsoy, M. B., and Pabuccuoglu, A.
(2007). The effect of acetaminophen
on oxidative modiﬁcation of low-
density lipoproteins in hypercholes-
terolemic rabbits. J. Clin. Biochem.
Nutr. 41, 27–31.
www.frontiersin.org November 2011 | Volume 2 | Article 72 | 5
Blough andWu Novel application of acetaminophen
Porubek, D. J., Rundgren, M., Harvi-
son, P. J., Nelson, S. D., andMoldeus,
P. (1987). Investigation of mech-
anisms of acetaminophen toxicity
in isolated rat hepatocytes with
the acetaminophen analogues 3,5-
dimethylacetaminophen and 2,6-
dimethylacetaminophen. Mol. Phar-
macol. 31, 647–653.
Prior, M. J., Lavins, B. J., and
Cooper, K. (2011). A randomized,
placebo-controlled trial of aceta-
minophen extended release for treat-
ment of post-marathonmuscle sore-
ness. Clin. J. Pain. PMID: 21760499.
[Epub ahead of print].
Rork, T. H., Hadzimichalis, N. M.,
Kappil, M. A., and Merrill, G.
F. (2006). Acetaminophen attenu-
ates peroxynitrite-activated matrix
metalloproteinase-2-mediated tro-
ponin I cleavage in the isolated
guinea pig myocardium. J. Mol. Cell.
Cardiol. 40, 553–561.
Schildknecht, S., Daiber, A., Ghisla, S.,
Cohen, R. A., and Bachschmid, M.
M. (2008). Acetaminophen inhibits
prostanoid synthesis by scavenging
the PGHS-activator peroxynitrite.
FASEB J. 22, 215–224.
Shertzer, H. G., Kendig, E. L., Nas-
rallah, H. A., Johansson, E., and
Genter, M. B. (2010). Protection
from olanzapine-induced metabolic
toxicity in mice by acetaminophen
and tetrahydroindenoindole. Int. J.
Obes. (Lond.) 34, 970–979.
Shertzer, H. G., Schneider, S. N.,
Kendig, E. L., Clegg, D. J., D’alessio,
D. A., and Genter, M. B. (2008).
Acetaminophen normalizes glucose
homeostasis in mouse models for
diabetes. Biochem. Pharmacol. 75,
1402–1410.
Trappe, T. A., Carroll, C. C., Dickin-
son, J. M., Lemoine, J. K., Haus, J.
M., Sullivan, B. E., Lee, J. D., Jemi-
olo, B.,Weinheimer, E. M., and Hol-
lon, C. J. (2011). Inﬂuence of aceta-
minophen and ibuprofen on skele-
tal muscle adaptations to resistance
exercise in older adults. Am. J. Phys-
iol. Regul. Integr. Comp. Physiol. 300,
R655–R662.
Trappe, T. A., Fluckey, J. D., White,
F., Lambert, C. P., and Evans,
W. J. (2001). Skeletal muscle
PGF(2)(alpha) and PGE(2) in
response to eccentric resistance
exercise: inﬂuence of ibuprofen
acetaminophen. J. Clin. Endocrinol.
Metab. 86, 5067–5070.
Trappe, T. A., White, F., Lambert, C.
P., Cesar, D., Hellerstein, M., and
Evans,W. J. (2002). Effect of ibupro-
fen and acetaminophen on postex-
ercise muscle protein synthesis. Am.
J. Physiol. Endocrinol. Metab. 282,
E551–E556.
Van Dyke, K., Sacks, M., and Qazi, N.
(1998). A new screening method to
detect water-soluble antioxidants:
acetaminophen (Tylenol) and
other phenols react as antioxidants
and destroy peroxynitrite-based
luminol-dependent chemilumines-
cence. J. Biolumin. Chemilumin. 13,
339–348.
Walker, E. M. Jr., Epling, C. P., Par-
ris, C., Cansino, S., Ghosh, P., Desai,
D. H., Morrison, R. G., Wright,
G. L., Wehner, P., Mangiarua, E.
I., Walker, S. M., and Blough, E.
R. (2007). Acetaminophen protects
against iron-induced cardiac dam-
age in gerbils.Ann. Clin. Lab. Sci. 37,
22–33.
Walker, E. M. Jr., Morrison, R. G.,
Dornon, L., Laurino, J. P., Walker,
S. M., Studeny, M., Wehner, P. S.,
Rice, K. M., Wu, M., and Blough,
E. R. (2009).Acetaminophen combi-
nations protect against iron-induced
cardiac damage in gerbils.Ann. Clin.
Lab. Sci. 39, 378–385.
Wu, M., Desai, D. H., Kakarla, S.
K., Katta, A., Paturi, S., Gutta, A.
K., Rice, K. M., Walker, E. M. Jr.,
and Blough, E. R. (2009a). Aceta-
minophenprevents aging-associated
hyperglycemia in aged rats: effect
of aging-associated hyperactiva-
tion of p38-MAPK and ERK1/2.
Diabetes Metab. Res. Rev. 25,
279–286.
Wu, M., Katta, A., Gadde, M. K.,
Liu, H., Kakarla, S. K., Fannin, J.,
Paturi, S., Arvapalli, R. K., Rice,
K. M., Wang, Y., and Blough,
E. R. (2009b). Aging-associated
dysfunction of akt/protein kinase
B: s-nitrosylation and aceta-
minophen intervention. PLoS ONE
4, e6430. doi:10.1371/journal.pone.
0006430
Wu, M., Falasca, M., and Blough,
E. R. (2011). Akt/protein kinase
B in skeletal muscle physiology
and pathology. J. Cell. Physiol. 226,
29–36.
Wu, M., Liu, H., Fannin, J., Katta, A.,
Wang, Y., Arvapalli, R. K., Paturi,
S., Karkala, S. K., Rice, K. M.,
and Blough, E. R. (2010). Aceta-
minophen improves protein trans-
lational signaling in aged skele-
tal muscle. Rejuvenation Res. 13,
571–579.
Yasukawa, T., Tokunaga, E., Ota,
H., Sugita, H., Martyn, J.
A., and Kaneki, M. (2005).
S-nitrosylation-dependent inacti-
vation of Akt/protein kinase B in
insulin resistance. J. Biol. Chem. 280,
7511–7518.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 19 September 2011; paper
pending published: 10 October 2011;
accepted: 24 October 2011; published
online: 09 November 2011.
Citation: Blough ER and Wu M (2011)
Acetaminophen: beyond pain and fever-
relieving. Front. Pharmacol. 2:72. doi:
10.3389/fphar.2011.00072
This article was submitted to Frontiers
in Experimental Pharmacology andDrug
Discovery, a specialty of Frontiers in
Pharmacology.
Copyright © 2011 Blough and Wu. This
is an open-access article subject to a non-
exclusive license between the authors and
Frontiers Media SA, which permits use,
distribution and reproduction in other
forums, provided the original authors and
source are credited and other Frontiers
conditions are complied with.
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery November 2011 | Volume 2 | Article 72 | 6
